PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
65.08%
Positive revenue growth while CVE is negative. John Neff might see a notable competitive edge here.
113.05%
Gross profit growth above 1.5x CVE's 36.05%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
348.34%
EBIT growth above 1.5x CVE's 18.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
348.34%
Operating income growth above 1.5x CVE's 18.09%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
220.00%
Net income growth above 1.5x CVE's 29.65%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
219.88%
EPS growth above 1.5x CVE's 62.50%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
216.96%
Diluted EPS growth above 1.5x CVE's 62.50%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.18%
Share reduction while CVE is at 0.03%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
0.03%
Diluted share change of 0.03% while CVE is zero. Bruce Berkowitz might see a minor difference that could widen over time.
0.18%
Maintaining or increasing dividends while CVE cut them. John Neff might see a strong edge in shareholder returns.
48.38%
OCF growth 1.25-1.5x CVE's 36.94%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
72.42%
FCF growth under 50% of CVE's 2783.33%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
5.78%
10Y revenue/share CAGR 1.25-1.5x CVE's 4.51%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
-30.01%
Negative 5Y CAGR while CVE stands at 4.51%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-56.16%
Negative 3Y CAGR while CVE stands at 4.51%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
28.20%
Positive OCF/share growth while CVE is negative. John Neff might see a comparative advantage in operational cash viability.
-39.36%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
141.84%
Net income/share CAGR 1.25-1.5x CVE's 120.59%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
164.85%
5Y net income/share CAGR 1.25-1.5x CVE's 120.59%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
-34.35%
Negative 3Y CAGR while CVE is 120.59%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
379.13%
Equity/share CAGR of 379.13% while CVE is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
46.13%
Equity/share CAGR of 46.13% while CVE is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-11.52%
Negative 3Y equity/share growth while CVE is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
168.41%
Dividend/share CAGR of 168.41% while CVE is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
-0.71%
Negative near-term dividend growth while CVE invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-6.37%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
100.00%
Inventory growth well above CVE's 6.55%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.34%
Positive asset growth while CVE is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.58%
BV/share growth above 1.5x CVE's 1.01%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-2.15%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-32.71%
We cut SG&A while CVE invests at 344.07%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.